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During early pregnancy, interleukin-1 (IL-1) is mainly produced and secreted by maternal decidua. Yet, its biological function
on placental cells is not well deﬁned. In this study, we employed JAR choriocarcinoma cell line as a model of human placental
trophoblast to study the eﬀect of IL-1. Treatment with recombinant human IL-1β resulted in signiﬁcant inhibition of JAR prolifer-
ation (P<. 05) paralleled with increased cytotoxicity. The inhibitory eﬀect was blocked by both IL-1 receptor antagonist (IL-1Ra)
andantihumanIL-1β monoclonalantibody.Analyzingthemodeofaction,IL-1β wasfoundtoinducecellcyclearrestintheG0/G1
phase and triggered apoptotic cell death. These ﬁndings demonstrated that IL-1 regulates human trophoblast growth by induction
of cell cycle delay and cell death.
Copyright © 2006 A. Nilkaeo and S. Bhuvanath. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
IL-1 is a pleiotropic proinﬂammatory cytokine produced by
both activated lymphoid and nonlymphoid cells. There are
t w ok n o w nf o r m so fI L - 1 ,am e m b r a n e - b o u n dI L - 1 α and a
secretory form IL-1β [1], both of which exert similar eﬀects.
Binding to their receptor complex, IL-1 leads to increased
activation of several transcription factors especially NF-κB.
This results in a wide spectrum of biological eﬀects, such as
local inﬂammation and endocrine eﬀect [2]. During preg-
nancy, IL-1 is mainly produced by maternal decidua [3]. IL-
1α and IL-1β production has been localized to macrophages,
glandular epithelium, and stromal cells in the endometrium
[4]. Several studies have suggested a potential role of IL-1
during pregnancy. IL-1 may function in the regulation of
blastocyst implantation [5] and in stimulating the produc-
tion ofendometrial leukemiainhibitory factor(LIF)produc-
tion [6]. IL-1 upregulation is thought to modulate decidual-
izationinanautocrine/paracrinemanner[7].Inmice,IL-1α,
IL-1β, and IL-1R mRNA are all expressed in the uterus dur-
ing the preimplantation period [8]. In addition, treatment
with IL-1Ra can block embryonic implantation [9]. These
studies support a potential functional role of IL-1 in decidu-
alization and implantation.
IL-1 may promote placental trophoblast invasion by
stimulating metalloproteinase (MMP-9) release by human
cytotrophoblast [10]. It is also associated with trophoblast
diﬀerentiation by increasing hCG production by isolated
ﬁrst-trimester villous trophoblast [11]a n dh u m a nc h o r i o -
carcinoma cell lines [12]. IL-1 also regulates the produc-
tion of other placental cytokines including M-CSF and IL-
6[ 13, 14]. Furthurmore, it was recently demonstrated that
maternal decidual IL-1 could stimulate proliferation of hu-
man ﬁrst trimester extravillous trophoblast cell lines [15]b y
induction of other growth factors especially IL-6 and LIF
[16, 17]. Increased cell proliferation and survival in the ex-
travillous trophoblast cell lines is mediated by the induction
of the phosphatidylinositol-3 kinase (PI3K) and mitogen-
activated protein kinase (MAPK) signal transduction path-
ways [18]. However, the eﬀect of IL-1 on villous trophoblast
is not well deﬁned. In this study, the eﬀect of IL-1 and its
mode of action on regulation of human placental villous tro-
phoblast proliferation was investigated.
MATERIALS AND METHODS
Cytokineandcellline
Recombinant human IL-1β and antihuman IL-1β mono-
clonal antibody were purchased from Peprotech Inc. (Rocky
Hill, NJ). IL-1Ra was purchased from Serotec (Kidling-
ton, Oxford). Insulin-transferrin-selenium growth supple-
ment (ITS) was purchased from Life Technology (Gaithers-
burg, MD). Actinomycin D was purchased from Amersham
Bioscience (Uppsala, Sweden). Choriocarcinoma cell line2 Mediators of Inﬂammation
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Figure 1: IL-1 inhibition of JAR proliferation. (a) JAR cells were cultured in the presence of increasing concentrations of IL-1 for 72 hours.
Relative cell numbers were measured by MTT assay. (b) LDH release assay was performed for cytotoxicity of IL-1. (c) JAR trophoblasts
were cultured for 72 hours with either IL-1 (50ng/mL) alone (A), IL-1 with anti- IL-1 antibody (5μg/mL) (B), IL-1 with anti- IL-1 anti-
body (10μg/mL) (C), IL-1 with IL-1Ra (50ng/mL) (D), IL-1 with IL-1Ra (100ng/mL) (E), IL-1Ra (100ng/mL) (F), anti- IL-1 antibody
(10μg/mL) (G), or untreated control (H). The MTT assay was then performed. The asterisks (∗, ∗∗, ∗∗∗P<. 05) represent signiﬁcant
diﬀerences between treatment and control groups as analyzed by One-Way ANOVA.
(JAR) is directly derived from a trophoblastic tumor of pla-
centa. It produces estrogen, progesterone, gonadotrophin,
and lactogen in culture. This cell line expresses IL-1 recep-
tor. The cells were maintained in RPMI 1640 (Life Technolo-
gies, Gaithersburg, MD) with 10% FBS and antibiotics (100
unit/mL of penicillin G, 100μg/mL of streptomycin sulfate,
and 0.25μg/mL of amphotericin B). The JAR cell line was
purchased from ATCC (Manassas, VA) and cultured at 37◦C
in 5% CO2.
MTTproliferationassay
Unless stated otherwise, JAR cells (10,000 cells/well) were
cultured in collagen I (50μg/mL) coated 96-well culture
plates, in a total volume of 200μL serum-free RPMI 1640
supplemented with insulin-transferrin-selenium (ITS) solu-
tion. Cells were cultured in the presence of increasing con-
centrations of recombinant human IL-1β (0–100ng/mL).
Both treatment and control groups were performed in 6–
8 replicate wells. The number of viable cells was then de-
termined after 72-hour incubation, by adding 1mg/mL of
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro-
mide (MTT) and incubating for a further 4 hours. Live cells
assimilated MTT, resulting in the accumulation of formazan
crystals. These were then solubilized with acid isopropanol
(90% isopropyl alcohol, 0.004N HCL) for 1 hour. The op-
tical density of this solution measured at 595nm is directly
related to the live cell numbers. These experiments were re-
peated at least three times to ensure the reproducibility. Inhi-
bition of the IL-1 eﬀect was tested by using antihuman IL-1β
monoclonal antibody and IL-1Ra.
Lactatedehydrogenase(LDH)assay
LDH release from trophoblasts was used to detect cytotox-
icity and was measured at the end of each proliferation
experiment. Brieﬂy, culture plates were centrifuged at
1500rpm for 15 minutes at room temperature to ensure ac-
cumulation of cells at the bottom of the wells. Cell-free cul-
ture media (100μL) was collected and then incubated with
100μL of the reaction mixture Cytotoxicity Detection Kit
(Boehringer Mannheim, Indianapolis, IN) for 30 minutes at
room temperature in the dark. 1N HCl (50μL) was added
into each well to stop the enzymatic reaction. The optical
density of the solution was then measured by using an ELISA
plate reader with a 490nm ﬁlter. Percent cytotoxicity to the
control was then determined.
Cellsynchronizationandstainingforﬂowcytometry
JAR cells were cultured in 4mL of RPMI 1640 containing
1 0 %F B Si n6 - w e l lc u l t u r ep l a t e( 1 0 0× 20mm) until 70–
80% conﬂuence was achieved. The culture medium was then
replaced with serum-free fresh medium and incubated with
0.1mM hydroxyurea for 24 hours. Synchronized JAR cells
were then cultured in 4mL of fresh RPMI 1640 in the pres-
ence of 5% FBS with or without IL-1β (50ng/mL) for 24,
32, and 48 hours. Cells were then trypsinized, centrifuged,
and resuspended into PBS and stained with propidium io-
dide solution. The percent cell in each cell cycle phase was
determined in each sample (30000 counts) using FACSCal-
ibur and ModFit LT software.
DNAladdering
JAR cells were cultured in 4mL of RPMI 1640 containing
10% FBS in 6-well culture plate until 70–80% conﬂuence
was achieved. Culture media were replaced with fresh ITS-
containing media with or without IL-1β (50ng/mL) and in-
cubated for 24, 48, and 72 hours. Cells were then washedA. Nilkaeo and S. Bhuvanath 3
Table 1: IL-1 modulation of cell cycle progression. Synchronized JAR cells were cultured with or without IL-1 at concentration of 50ng/mL
for 24, 32, and 48 hours. The cells were harvested and stained with propidium iodide. Percent cells (mean ± SEM) in each cycle phase were
then analyzed in cells collected using ﬂow cytometer. The asterisk (∗, P<. 0001) represents signiﬁcant diﬀerence between antimalarial drug
treatment and control groups as analyzed by T-test.
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FBS alone
FBS + IL-1β
with cold PBS and lysed with lysis solution. DNA sample was
thenextractedfromthesolutionusingaphenol-chloroform-
isoamylalcoholextractionprotocol.TheDNAconcentration
was determined using a spectrophotometer (OD260). DNA
(2μg) samples, along with positive controls, were then sub-
jected to agarose gel (1.5%) electrophoresis. DNA ladder was
analyzed by ethidium bromide staining and visualized using
UV transilluminator.
Insitudetectionofapoptoticcelldeath
JAR cells were cultured in 4mL of RPMI 1640 containing
10% FBS in 6-well culture plate containing a glass slide until
70–80% conﬂuence was achieved. Culture medium was re-
placedwithfreshmediumcontainingITSwithorwithoutIL-
1β (50ng/mL) and incubated for 72 hours. Apoptosis stain-
ing was carried out using an Apoptosis Detection Kit (R&D
systems, Minneapolis, MN) in culture plate as follows. Glass
slides were washed with ice cold PBS then ﬁxed using freshly
prepared paraformaldehyde solution 3.7% for 10 minutes at
room temperature. Slides were then rinsed with PBS and in-
cubated in permeabilization solution for 30 minutes at room
temperature. Slides were then rinsed with washing buﬀer
and incubated with TdT reaction mixture for 60 minutes at
37◦C. The labeling reaction was stopped and then incubated
with streptavidin-FITC for 10 minutes at room temperature.
Slides were then washed with PBS and visualized using ﬂu-
orescent microscopy. Similar experiments were conducted
without glass slide and apoptotic cells were determined us-
ing ﬂow cytometry.
Statistics
Data are presented as mean ± standard error of the mean
(SEM). Diﬀerences in data between two groups in cell cycle
studies were analyzed using the Student t test. In cell prolif-
eration and cytotoxicity experiments, Dunnett’s method of
One-Way ANOVA was used to assess diﬀerences among con-
trol groups and treatment groups.
RESULTS
IL-1inhibitionofhumanplacental
trophoblastproliferation
The overall purpose of this project was to investigate the
eﬀect of IL-1β and its mode of action on JAR cell prolif-
eration. The proliferative response of JAR cells to IL-1 is
shown in Figure .I L - 1 β, as low as 0.01ng/mL, inhibited JAR
trophoblast proliferation compared to the control groups
(∗P<. 05).AthighestdoseofIL-1β usedinthisstudy,prolif-
eration was diminished by 46%. In a related study, the cyto-
toxic eﬀect of IL-1β on JAR cells was determined by mea-
suring the release of cytosolic LDH. The LDH concentra-
tion in conditioned media was proportional to cell death,
and IL-1β treatment in these cells led to the increase of
LDHrelease.Percentcytotoxicitytothecontrol(Figure 1(b))
was increased in dose-dependent fashion, indicating that IL-
1β promoted cytotoxicity. To conﬁrm the inhibitory eﬀect
of IL-1 on JAR cell proliferation, blocking of proliferation4 Mediators of Inﬂammation
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Figure 2:IL-1inductionofDNAfragmentation.JARcellswerecul-
turedinserum-freeRPMI1640withorwithoutIL-1(50ng/mL)for
24,48,and72hours.InhibitionofDNAfragmentationwasalsoper-
formedusingIL-1Ra.DNAsampleswereextractedandfractionated
by agarose gel (1.5%) electrophoresis and DNA ladders were visual-
ized after gel staining.
inhibition was studied by using IL-1Ra and antihuman IL-
1β monoclonal antibody. IL-1Ra (50 and 100ng/mL) were
preincubated with JAR cells for 1 hour at 37◦C, prior to the
addition of IL-1β (to ﬁnal concentration of 50ng/mL). Neu-
tralizing activity of antihuman IL-1β monoclonal antibody
wasstudiedbyincubatingtheantibodywithIL-1β foratleast
one hour prior to the addition to the cell culture. The MTT
assay was then performed after 72-hour incubation. Figure
showed that IL-1β (50ng/mL) inhibited JAR cells by 55% (A,
∗P<. 05) compared to the control groups (H). Antihuman
IL-1 antibody at 5 and 10μg/mL blocked IL-1β activity by
34% and 28%, respectively (B, C, ∗∗P<. 05). IL-1Ra at a
concentration of 50 and 100ng/mL blocked IL-1β activity by
83% (D, E, ∗∗∗P<. 05). These ﬁndings conﬁrmed that IL-1
exerts its inhibitory action via speciﬁc receptor.
InvolvementofIL-1andcellcycleprogression
To determine the eﬀe c to fI L - 1o nc o n t r o lo fJ A Rc e l lc y -
cle progression, the DNA content was measured by ﬂow cy-
tometry, and the percentage of cells in each stage was an-
alyzed and compared. As shown in Table 1, the number of
c e ll si ne a c hp h a s ew a sc o m p a ra b l ei nb o t hc o n tr o la n dtr e a t -
ment groups at 24 hours after cell cycle restimulation. At 32
hours, the percentage of cells in the G0/G1 phase was in-
creased (∗, P<. 0001), while the percentage of cells in S
phase was decreased in treatment groups compared to the
control group (FBS alone). These ﬁndings indicated that IL-
1 delayed cell cycle progression stimulated with FBS, result-
ing in accumulation of cells in G0/G1 phase. This could also
indicate that IL-1 may inhibit DNA synthesis since the num-
ber of cells in the S phase was lowered. Interestingly, changes
in the percentage of cells in the G2/M phase between the test
and control group were not observed. Within the treatment
groups, the number of cells deposited in the G0/G1 phase at
48 hours was not diﬀerent from the 32-hour treatment indi-
cating that the IL-1 eﬀect on delaying cell cycle lasted at least
for 48 hours. In addition, treatment with IL-1 for more than
48 hours resulted in detached dead cells. This indicated that
inhibition of proliferation is also accompanied by the induc-
tion of cell death.
IL-1inductionofapoptosis
Since the increase of cytotoxicity and cell death resulting
from IL-1 treatment of JAR cells, we therefore hypothesized
that this could be attributed to the induction of apoptosis.
To test this hypothesis, DNA fragmentation, as a marker of
apoptosis, in JAR cells treated with IL-1 was determined us-
ing both DNA laddering technique and enzymatic in situ la-
beling of apoptotic cells.
In DNA ladder analysis (Figure 2), fragmented DNA was
observed in cells treated with IL-1β after both 48- and 72-
hour incubation as well as in cells that had been treated with
actinomycin D (positive control, 1μg/mL) for 4 hours. In
contrast, there was no obvious DNA ladder in the untreated
control group. In addition, when cells were incubated with
IL-1β and IL-1Ra (50ng/mL) for 72 hours, the DNA lad-
ders were markedly decreased. This indicated that IL-1β in-
duction of apoptotic cell death can be prevented by IL-1Ra.
Further analysis to conﬁrm the induction of apoptosis us-
ing enzymatic in situ labeling (Figure 3) revealed that IL-1β
(50ng/mL) (C) treatment for 72 hours could lead to apopto-
siscelldeathasvisualizedbyﬂuorescentmicroscopy,whereas
there was little spontaneous cell death observed in the un-
treated control group (B). In addition, this result was consis-
tent with similar experiments analyzed by using ﬂow cytom-
etry (D).
DISCUSSION
Maternal immune response during pregnancy is thought to
be detrimental to the survival of the fetus, but in fact it
may be beneﬁcial. The success of pregnancy relies on ad-
equate growth of the placenta. The mechanism of regu-
lation of placental growth is thought to be hormone de-
pendent, and perhaps also under the inﬂuence of mater-
nal inﬂammatory cytokines. In 1984, Wegmann proposed
the “immunotrophism” hypothesis stating that maternal im-
mune response to the fetus has a beneﬁcial role in regulating
placental growth and development [19], whereas some cy-
tokines may play a role in the downregulation of placental
trophoblast development. These cytokines could be catego-
rized as immunodystrophism cytokines. IL-1, a mediator of
inﬂammation at maternal-fetal interface, is produced mainlyA. Nilkaeo and S. Bhuvanath 5
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Figure 3: IL-1 induction of apoptosis. JAR cells were cultured in serum-free RPMI 1640 with or without IL-1 and incubated for 72 hours.
In situ cell death detection was then performed and apoptosis was visualized by ﬂuorescent microscopy. Apoptotic cells showed a green
ﬂuorescent nucleus. (a) Nuclease treated (positive control); (b) untreated control; (c) JAR treated with IL-1 (50ng/mL). Similar experiments
were conducted without glass slide and apoptotic cells were determined using ﬂow cytometry (d).
by decidua with a tissue level of 175pg/mg total protein
and secretory rate at 190pg/ml/24 hours [15]. In the present
study, this proinﬂammatory cytokine was investigated for its
role in the inhibition of trophoblast prolilferation. The ﬁnd-
ings in this study provided a new insight into the interac-
tion between the maternal imune response and the biology
oftrophoblastcells.Inapreviousstudyusinginvasiveextrav-
illous trophoblast cell lines, maternal decidual IL-1 acted as
a growth factor for these cells via the activation of PI3K and
MAPK pathways [18]. This was a new evidence that placen-
talgrowthisalso,inpart,controlledbythematernalcytokine
[15].
In contrast to invasive extravillous trophoblast cell lines,
in JAR choriocarcinoma cell line, which has the character-
istics of early placental trophoblast residing on the ﬂoating
placental villi, IL-1 was found to have the opposite eﬀect.
Recombinant human IL-1β inhibited JAR proliferation and
this eﬀect was blocked by using IL-1-Ra or antihuman IL-1β
monoclonal antibody, indicating a speciﬁc biological activ-
ity mediated through the receptor complex. Furhermore, the
inhibition of proliferation by IL-1 was shown to be mediated
by the induction of cell cycle arrest followed by the induction
of apoptotic cell death. Consistenly, this biological activity of
IL-1 was also demonstrated in other studies. For example,
IL-1 was elevated during labour and preterm premature rup-
ture of the membrane and was found to induce apoptosis
of placental membrane [20]. In a mouse model of preterm
delivery, trophoblastic apoptosis was observed accompanied
with the increase serum level of TNF-α and IL-1α [21]. In
other studies, the antiproliferative eﬀect of IL-1 on human
melanoma is mediated by G0/G1 arrest [22]. More speciﬁ-
cally, the IL-1 growth arrest of melanoma is induced by hy-
pophosphorylation of the retinoblastoma susceptibility gene
product RB [23], but it is independent of p53 and p21/WAF1
function [24].
Collectively, the data presented in this study indicate that
IL-1 regulates human placental trophoblast growth by delay-
ing cell cycle transition followed by induction of apoptosis.
ThispropertymayrenderIL-1asanimmunodistrophismcy-
tokine. In addition, this could also raise an interesting issue6 Mediators of Inﬂammation
concerning choriocarcinoma, which is often an outcome of
hydatidiform mole, whether this complex interplay between
maternal IL-1 and placental trophoblast is similar to the in-
teraction of IL-1 with hydatidiform mole in vivo.
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